News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Addex Therapeutics focused on securing new partnerships to fund promising treatments

Addex Therapeutics Ltd

Addex Therapeutics co-founder and CEO Tim Dyer speaks to Thomas Warner from Proactive about the work that the central nervous system-focused clinical-stage pharmaceutical company has been doing in the promising area of allosteric modulation. He explains that company is currently collaborating with Johnson & Johnson on a phase two study for epilepsy, with results expected in Q2 of the following year. Additionally, Addex is developing treatments for chronic cough, schizophrenia, and cognition, with the latter receiving a grant from the European Union. Dyer explains that the company's unique approach to allosteric modulation offers a competitive edge in drug discovery, setting them apart from competitors. Their long-term strategy revolves around advancing their programs and securing partnerships to ensure steady cash inflows, especially given the challenging capital market environment. With seven programs in the pipeline and two already partnered, Addex is poised for significant growth in the coming years. Dyer says that "at the moment we continue to move the programs forward... we're very focused today on securing cash inflows to keep the business going through partnerships." Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

October 05, 2023 11:20 AM Eastern Daylight Time

Video
Article thumbnail News Release

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Shield Therapeutics PLC

Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics. Davison gives an overview of what readers can expect from the note, highlighting Shield's recent half-year results and accompanying financing transactions. The company's burgeoning relationship with commercial partner Viatris is a key focus. While the product's trajectory is promising, Davison explains that Shield has been grappling with the challenge of drug reimbursements in the US, leading to the incurring of some costs. However, plans are underway to assist doctors in navigating this system, with a view to securing a higher average drug price. Davison suggests that Shield's ability to increase that average price will be a "key metric going forward." He concludes by saying that "the trajectory is going extremely well, [they' really just want to get the pricing issue sorted now and it should be a great story." Davison's research note is available on the Proactive website as is a interview with Shield Therapeutics' CEO Greg Madison. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 05, 2023 04:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

Northern Leaf "on the road in terms of sales" ahead of London listing

Northern Leaf

Northern Leaf CEO Don Perrott speaks to Thomas Warner from Proactive London about the Jersey-based medical cannabis company's progress towards a potential AIM-listing later this year. Perrott gives an overview of the business and its achievements since being incorporated in 2019, highlighting its 100,000 square-foot glasshouse facility that produces six to eight tonnes of medical cannabis annually and its its EU Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP certifications). He discusses the benefits the advantages of operating in Jersey, which include a supportive government and competitive electricity costs. Northern Leaf is gearing up for a listing on AIM in the fourth quarter, with substantial progress already made in its IPO preparations. Perrott emphasises the commitment to producing high-quality, consistent medical cannabis and says the company is "on the road in terms of sales" with a shipment already on its way to Australia and deliveries to the UK and Germany scheduled. Perrott also expresses confidence in Northern Leaf's ability to navigate an often complex regulatory environment, saying that the company is "on top of regulations" and embracing the opportunities being created. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 05, 2023 03:57 AM Eastern Daylight Time

Video
Article thumbnail News Release

Shield Therapeutics "couldn't be more pleased" with Viatris collaboration

Shield Therapeutics PLC

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) CEO Greg Madison speaks to Thomas Warner after a busy week for the commercial stage pharmaceutical company, which included the release of its interim results and the announcement of a major fundraise. He highlights the success of the fundraise, which comprised US$20 million from a new senior debt facility as well as an equity fundraise (split between a share placing, a subscription and an offering to retail investors) that brought in an additional US$6 million. He explains that the new funding is going to be put to use in "paying off an existing loan, increasing our working capital needs and then certainly some commercial investments to accelerate the curve that we're seeing here." The curve he describes is the marked increase in demand for Shield's Accrufer product, which is a stable, non-salt based oral therapy for adults with iron deficiency that is designed to avoid some of the unwanted side-effects of conventional iron tablets. He says he "can't speak highly enough about the dedication and passion of [his] team at Shield, but also about our partner Viatris... we made an excellent choice... we couldn't be more pleased with the partnership and the collaboration we're seeing." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 05, 2023 03:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

Nuformix to fund its unlicensed programs with NXP001 windfall

Nuformix PLC

Nuformix PLC (LSE:NFX) executive director Dr Dan Gooding speaks to Proactive after the pharmaceutical development company announced it is to receive new immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Dr. Gooding explains that Oxilio has now purchased patents from Nuformix that it had previously been licencing, resulting in significant near-term payments to Nuformix. This financial boost will aid Nuformix in advancing their unlicensed programs, specifically NXP002 and NXP004. Despite the patent sale, Nuformix retains future value from NXP001 through development milestones and royalties. Dr. Gooding also highlights Nuformix's work with NXP002 on lung fibrosis, a severe disease with limited treatment options. He explains that Nuformix's approach of repurposing existing drugs means a reduction in research time and costs. NXP002 is a modified version of a drug initially approved in Japan for asthma and skin scarring treatment. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 05, 2023 03:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

NetScientific "well positioned for growth" when venture capital market turns

NetScientific PLC

NetScientific PLC (AIM:NSCI) CEO Dr Ilian Iliev speaks to Thomas Warner from Proactive after the investment and commercialisation group published its interim results for the six months ended 30 June 2023. Dr Iliev provides some context for the half-year results, saying that the company has been working hard and focusing on executing its strategy in what has been a "difficult period" for venture capital. He goes on to give an overview of the half-year results, saying that he's "happy to report strong progress in the first half of the year" and highlighting the realisation of "roughly £800,000 in profitable partial exists from the portfolio" during the period. He addresses how the challenges affecting the wider venture capital sector are playing out at NetScientific and expresses confidence in what the company calls its "evergreen" strategy, saying that its "well positioned for growth when inevitably the cycle turns around... we are not venture capital tourists - this is what we do on a daily basis and we are positioning ourselves for the inevitable turnaround." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 04, 2023 04:17 AM Eastern Daylight Time

Video
Article thumbnail News Release

Unwiring.org Takes Bold Steps to Reform Social Media For a Healthier, More Connected Future

Unwiring

Unwiring officially launches to empower individuals in the fight against social media's negative impacts and unethical practices. The organization is led by Saahil Mishra and a diverse team of passionate teens who’ve developed several initiatives to catalyze positive change within social media. “I worry about the impact of social media on my generation. A surge in social isolation, mental health issues, disinformation, and political polarization has challenged our connection on both an interpersonal and societal level,” said Saahil Mishra, founder and social media activist. Mishra also serves as a research assistant at Stanford Social Media Lab and writer for the Poynter Institute’s Media Wise. Earlier this year, Mishra participated in his first TEDx Talk event in San Francisco. Unwiring is educating and empowering young people to drive real, representative change within social media. The team curates timely educational resources including a series of self-produced online videos, curriculum on social media’s inner workings and impacts, and editorial pieces centered around the youth perspective on social media’s harms and possible solutions. Unwiring also is hosting a ReDesign challenge for youth to pose ideas for social media reformation this fall and a youth summit in 2024. United States Surgeon General Dr. Vivek Murthy issued a call for urgent action by policymakers, technology companies, researchers, families, and young people alike to gain a better understanding of the full impact of social media use. Recent research shows that adolescents who spent more than three hours daily on social media faced double the risk of experiencing poor mental health outcomes, such as symptoms of depression and anxiety. “When we advocate for internal platform changes, business model regulations, major culture and paradigm shifts, we can together build a healthier more connected future,” adds Mishra. “We invite teens to join us in this important movement by sharing their stories with us.” Visit unwiring.org and engage on Instagram, YouTube, TikTok, X formerly known as Twitter: @unwiring_org. Contact Details Unwiring Anne Shanahan, Community Relations Liaison +1 562-810-3016 ashanahan@unwiring.org

October 03, 2023 08:05 AM Pacific Daylight Time

Video
Article thumbnail News Release

NuggMD Launches Its Leading Marijuana Telemedicine Service in Delaware

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, is launching its service in Delaware for just $99 for a limited time. Since its founding in 2015, NuggMD has connected over 1,000,000 patients to their medical marijuana physicians. It's legal to possess and use cannabis in the state, but adult-use sales aren't expected to begin until November 2024 at the soonest, and more likely later in 2025. Medical patients in the state opposed the option to allow the existing, tightly-regulated medical dispensaries to begin adult-use sales earlier due to fears that there wouldn't be enough cannabis to serve both medical and recreational needs, which would cause a spike in prices. "It's understandable that patients would be worried about a spike in prices with an uncontrolled launch of recreational sales," says Alex Milligan, CMO and co-founder of NuggMD. "It has happened in other states, leaving patients in a bad situation. But the current situation brings about other safety concerns. State residents can possess cannabis and use it legally, but can't buy safe, tested weed unless they're patients." "I don't suggest you turn to the black market while waiting for dispensaries to open," says Kam Babazade, COO and co-founder of NuggMD. "Recent tests on black market products on the East Coast have shown contaminants, synthetic cannabinoids, and major discrepancies in potency. This is something you especially want to avoid if you have significant medical issues." "We have diverted over a million patients from the black market now," says Collin Mann, NuggMD co-founder and CEO. "Delaware was wise to allow telemedicine so even more patients can be turned toward the legal, tested, and safe products in the state's existing dispensaries." NuggMD's platform is available from 8 am to 10 pm seven days a week. No appointment is needed, and patients who don't qualify for their state's medical cannabis program won't be charged for their evaluation. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Delaware, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Delaware, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com/Delaware. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

October 02, 2023 05:28 PM Eastern Daylight Time

Article thumbnail News Release

Redsense Medical announces company has begun trading on the OTCQX under ticker 'RDSMF'

Redsense Medical

Redsense Medical CEO Pontus Nobreus joined Steve Darling from Proactive to share significant updates regarding the company's innovative Redsense System. This system plays a crucial role in monitoring and alerting healthcare providers in cases of blood leakage during hemodialysis treatments, addressing one of the most serious safety concerns in this medical field. The Redsense System comprises a patented fiber optic sensor designed for use with either a venous needle or central venous catheter, linked to an alarm unit. The system has been developed with a strong focus on meeting the stringent safety requirements of healthcare providers in the dialysis sector. Alarmingly, globally, 21 individuals lose their lives each week due to blood leakage during hemodialysis, making this technology a critical advancement in patient care. One major development for Redsense Medical is its recent listing on the OTCQX market under the ticker symbol 'RDSMF.' The United States is a pivotal market for the company, with 99% of its revenue in 2022 generated from the US. The company is actively planning to expand its presence in the US market, providing easier access for US investors to participate in their growth journey. Looking ahead to the remainder of 2023 and 2024, Redsense Medical has ambitious goals, including continued growth in the US market and raising awareness about the importance of monitoring devices in home dialysis. Additionally, the company is set to launch a new product called "The Clamp," which will further enhance patient safety during hemodialysis treatments. Overall, Redsense Medical's dedication to improving patient safety and healthcare outcomes in the field of hemodialysis positions it as a key player in the medical technology industry, and its expansion plans in the US market are poised to make a significant impact. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 29, 2023 01:39 PM Eastern Daylight Time

Video
1 ... 7273747576 ... 250